In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Sparsentan is the first dual pathway blocker. Its usage and dosage should be det···【more】
Release date:2026-03-18Recommended:315
Elacestrant, an estrogen receptor antagonist developed by the Italian company Me···【more】
Release date:2026-03-16Recommended:258
Elacestrant, while exerting its therapeutic effects, can also cause some side ef···【more】
Release date:2026-03-16Recommended:260
Regarding the dosage of elacestrant, in addition to the recommended dose, approp···【more】
Release date:2026-03-16Recommended:270
Elacestrant is an estrogen receptor antagonist developed by the Italian company ···【more】
Release date:2026-03-16Recommended:276
Capmatinib is a targeted therapy for non-small cell lung cancer with MET exon 14···【more】
Release date:2026-03-13Recommended:324
Capmatinib (Tabrecta) is a highly selective MET receptor tyrosine kinase inhibit···【more】
Release date:2026-03-13Recommended:407
Ixazomib, as a novel targeted therapy, blocks the growth and proliferation of tu···【more】
Release date:2026-03-13Recommended:298
Ixazomib is an oral proteasome inhibitor primarily used clinically to treat mult···【more】
Release date:2026-03-13Recommended:354
Ibrutinib is an oral Bruton's tyrosine kinase (BTK) inhibitor that was first···【more】
Release date:2026-03-12Recommended:286
Ibrutinib (Imbruvica) is an oral Bruton's tyrosine kinase (BTK) inhibitor us···【more】
Release date:2026-03-12Recommended:281
Ibrutinib is a small molecule that acts as a potent, irreversible inhibitor of B···【more】
Release date:2026-03-12Recommended:292